Ascletis Pharma Inc.

Ascletis Pharma Inc. is a fully integrated biotechnology company headquartered in Hangzhou, China. The company is dedicated to the research, development, production, marketing, and sale of innovative pharmaceutical products. Its mission is to develop and commercialize potential best-in-class and first-in-class therapeutics to address significant unmet medical needs globally.

Ascletis focuses on three primary therapeutic areas: metabolic diseases, viral diseases, and oncology, with additional interests in dermatology. Key marketed products include Ritonavir tablets, GANOVO®, and ASCLEVIR® for Hepatitis C. The company's pipeline features numerous drug candidates, such as ASC30 for obesity and diabetes, ASC22 for HBV and HIV functional cure, ASC10 for COVID-19 and monkeypox, ASC40 for NASH, acne, and glioblastoma, and ASC61 for advanced solid tumors. Ascletis leverages proprietary technologies including Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT) to advance its drug discovery efforts.

Led by Founder, Chairman, and CEO Dr. Jinzi Jason Wu, Ascletis is an R&D-driven biotech listed on the Hong Kong Stock Exchange. Recent notable developments include the completion of enrollment in a U.S. Phase II study for ASC30 (oral GLP-1R agonist) for diabetes in April 2026, with topline data anticipated in the third quarter of 2026. In March 2026, the company announced positive topline results from a U.S. Phase II study for its ultra-long-acting subcutaneous depot formulations of ASC30 for obesity. Additionally, in December 2025, China's National Medical Products Administration accepted the New Drug Application for denifanstat (ASC40), a first-in-class FASN inhibitor for acne treatment.